Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Employees - 437, CEO - Dr. R. Scott Struthers Ph.D., Sector - Healthcare, Country - US, Market Cap - 2.69B

Altman ZScore(max is 10): 15.35, Piotroski Score(max is 10): 2, Working Capital: $1315704000, Total Assets: $1434592000, Retained Earnings: $-952110000, EBIT: -338854000, Total Liabilities: $109787000, Revenue: $1039000

AryaFin Target Price - $0.82 - Current Price $28.87 - Analyst Target Price $74.33